Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions

March 27th 2012

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Improved Survival in Women With Invasive Epithelial Ovarian Cancer and Germline BRCA Gene Mutations

March 26th 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Spector Discusses the Complexities of Cancer

March 26th 2012

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer

Dr. Dunleavy Discusses ABC DLBCL Research

March 23rd 2012

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research

MET Receptor Pathway: A Bounty of Targeted Options Explored

March 23rd 2012

The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.

Dr. Chang on Combining HER2 Targeted Therapies

March 22nd 2012

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

Massachusetts General Hospital Cancer Center: At the Forefront of Personalized Care

March 22nd 2012

The Massachusetts General Hospital (MGH) Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs, as well as an extensive array of support and educational services.

Five Questions for Jill M. Siegfried, PhD

March 22nd 2012

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

Analyzing Disease Flares: Impact of Discontinuing Targeted Therapy Unclear

March 21st 2012

It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.

Drug Interactions Significantly Reduce Targeted Therapy Efficacy

March 16th 2012

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

Dr. Perez-Soler on the Future of Lung Cancer Therapies

March 13th 2012

Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies

Taking a Leap in Cancer Diagnostics: Clarient Enters New Era in Molecular Tumor Testing, Drug Discovery Research

March 9th 2012

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Belani Discusses Driver Mutations in NSCLC

March 7th 2012

Dr. Chandra Belani from Penn State Hershey Cancer Institute Discusses Driver Mutations in NSCLC

Dr. Ramaswamy Discusses Tumor Heterogeneity

March 7th 2012

Dr. Sridhar Ramaswamy from the Massachusetts General Hospital Cancer Center Discusses Tumor Heterogeneity

The Retreatment Strategy: Would It Work With the Same Molecularly Targeted Therapy?

February 23rd 2012

Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.

Dr. Leyland-Jones Discusses Genome Sequencing

February 20th 2012

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

John Theurer Cancer Center at Hackensack University Medical Center: Providing Extraordinary Care to the Community

February 14th 2012

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

Dr. Ramaswamy on Dormant Tumor Cells and Resistance

February 13th 2012

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials